CVS HEALTH CORPORATION Net Income (Loss) Available to Common Stockholders, Diluted
CVS HEALTH CORPORATION (CVS) reported Net Income (Loss) Available to Common Stockholders, Diluted of $2.98 billion for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Income Statement › Net Income
us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted · last filed 2026-08-05
- CVS HEALTH CORPORATION net income (loss) available to common stockholders, diluted for the quarter ending 2026-06-30 was $2.98B, a 191.77% increase year-over-year.
- CVS HEALTH CORPORATION net income (loss) available to common stockholders, diluted for the quarter ending 2026-03-31 was $2.94B, a 65.43% increase year-over-year.
- CVS HEALTH CORPORATION net income (loss) available to common stockholders, diluted for the quarter ending 2025-12-31 was $2.94B, a 79.01% increase year-over-year.
- CVS HEALTH CORPORATION net income (loss) available to common stockholders, diluted for the quarter ending 2025-09-30 was -$3.98B, a 4668.97% decline year-over-year.
- CVS HEALTH CORPORATION net income (loss) available to common stockholders, diluted for fiscal 2025 was $1.77B, a 61.68% decline from fiscal 2024.
- CVS HEALTH CORPORATION net income (loss) available to common stockholders, diluted for fiscal 2024 was $4.61B, a 44.70% decline from fiscal 2023.
- CVS HEALTH CORPORATION net income (loss) available to common stockholders, diluted for fiscal 2023 was $8.34B, a 93.55% increase from fiscal 2022.
- CVS HEALTH CORPORATION net income (loss) available to common stockholders, diluted for fiscal 2022 was $4.31B, a 46.12% decline from fiscal 2021.
| Period end | Net Income (Loss) Available to Common Stockholders, Diluted 3 month | Net Income (Loss) Available to Common Stockholders, Diluted 6 month | Net Income (Loss) Available to Common Stockholders, Diluted 9 month | Net Income (Loss) Available to Common Stockholders, Diluted 12 month |
|---|---|---|---|---|
| 2026-06-30 | $2.98B 10-Q · filed 2026-08-05 | $5.92B 10-Q · filed 2026-08-05 | $8.87B derived: sum of 3 quarters · filed 2026-08-05 | $4.89B derived: sum of 4 quarters · filed 2026-08-05 |
| 2026-03-31 | $2.94B 10-Q · filed 2026-05-06 | $5.89B derived: sum of 2 quarters · filed 2026-05-06 | $1.91B derived: sum of 3 quarters · filed 2026-05-06 | $2.93B derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-12-31 | $2.94B derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-10 | -$1.03B derived: sum of 2 quarters · filed 2026-02-10 | -$11.00M derived: sum of 3 quarters · filed 2026-08-05 | $1.77B 10-K · filed 2026-02-10 |
| 2025-09-30 | -$3.98B 10-Q · filed 2025-10-29 | -$2.95B derived: sum of 2 quarters · filed 2026-08-05 | -$1.18B 10-Q · filed 2025-10-29 | $469.00M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-06-30 | $1.02B 10-Q · filed 2026-08-05 | $2.80B 10-Q · filed 2026-08-05 | $4.44B derived: sum of 3 quarters · filed 2026-08-05 | $4.53B derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-03-31 | $1.78B 10-Q · filed 2026-05-06 | $3.42B derived: sum of 2 quarters · filed 2026-05-06 | $3.51B derived: sum of 3 quarters · filed 2026-05-06 | $5.28B derived: sum of 4 quarters · filed 2026-05-06 |
| 2024-12-31 | $1.64B derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-10 | $1.73B derived: sum of 2 quarters · filed 2026-02-10 | $3.50B derived: sum of 3 quarters · filed 2026-02-10 | $4.61B 10-K · filed 2026-02-10 |
| 2024-09-30 | $87.00M 10-Q · filed 2025-10-29 | $1.86B derived: sum of 2 quarters · filed 2025-10-29 | $2.97B 10-Q · filed 2025-10-29 | $5.02B derived: sum of 4 quarters · filed 2026-02-10 |
| 2024-06-30 | $1.77B 10-Q · filed 2025-07-31 | $2.88B 10-Q · filed 2025-07-31 | $4.93B derived: sum of 3 quarters · filed 2026-02-10 | $7.19B derived: sum of 4 quarters · filed 2026-02-10 |
| 2024-03-31 | $1.11B 10-Q · filed 2025-05-01 | $3.16B derived: sum of 2 quarters · filed 2026-02-10 | $5.42B derived: sum of 3 quarters · filed 2026-02-10 | $7.32B derived: sum of 4 quarters · filed 2026-02-10 |
| 2023-12-31 | $2.05B derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-10 | $4.31B derived: sum of 2 quarters · filed 2026-02-10 | $6.21B derived: sum of 3 quarters · filed 2026-02-10 | $8.34B 10-K · filed 2026-02-10 |
| 2023-09-30 | $2.26B 10-Q · filed 2024-11-06 | $4.16B derived: sum of 2 quarters · filed 2024-11-06 | $6.30B 10-Q · filed 2024-11-06 | $8.63B derived: sum of 4 quarters · filed 2025-02-12 |
| 2023-06-30 | $1.90B 10-Q · filed 2024-08-07 | $4.04B 10-Q · filed 2024-08-07 | $6.37B derived: sum of 3 quarters · filed 2025-02-12 | $2.96B derived: sum of 4 quarters · filed 2025-02-12 |
| 2023-03-31 | $2.14B 10-Q · filed 2024-05-01 | $4.47B derived: sum of 2 quarters · filed 2025-02-12 | $1.06B derived: sum of 3 quarters · filed 2025-02-12 | |
| 2022-12-31 | $2.33B derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-12 | -$1.07B derived: sum of 2 quarters · filed 2025-02-12 | $4.31B 10-K · filed 2025-02-12 | |
| 2022-09-30 | -$3.41B 10-Q · filed 2023-11-01 | $1.98B 10-Q · filed 2023-11-01 | ||
| 2021-12-31 | $8.00B 10-K · filed 2024-02-07 | |||
| 2016-06-30 | $920.00M 10-Q · filed 2016-08-02 | $2.06B 10-Q · filed 2016-08-02 | ||
| 2016-03-31 | $1.14B 10-Q · filed 2016-05-03 | |||
| 2015-06-30 | $1.26B 10-Q · filed 2016-08-02 | $2.48B 10-Q · filed 2016-08-02 | ||
| 2015-03-31 | $1.22B 10-Q · filed 2016-05-03 | |||
| 2010-12-31 | $3.43B 10-K · filed 2011-02-18 | |||
| 2009-12-31 | $3.70B 10-K · filed 2011-02-18 | |||
| 2008-12-31 | $3.21B 10-K · filed 2011-02-18 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| PETMED EXPRESS INC (PETS) | United States | $0.034B | -1.41 |